LLL12
Based on 1 publication(s) in Google Scholar
LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth.
For research use only. We do not sell to patients.
- Purity: 99.45%
- CAS No.: 1260247-42-4
- Formula: C14H9NO5S
- Molecular Weight:303.29
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
JAK/STAT Compound Library
HY-L008
-
Kinase Inhibitor Library
HY-L009
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) LLL12
More
Biological Activity
|
p-STAT3 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| DU-145 | IC50 |
0.19 μM
Compound: LLL12
|
Antiproliferative activity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay
Antiproliferative activity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay
|
[PMID: 24176397] |
| HEL | IC50 |
1.46 μM
Compound: LLL12
|
Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 33689932] |
| HPAC | IC50 |
0.16 μM
Compound: 13, LLL12
|
Cytotoxicity against human HPAC cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HPAC cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23651330] |
| HT-29 | IC50 |
0.11 μM
Compound: LLL12
|
Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay
Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay
|
[PMID: 24176397] |
| MDA-MB-231 | IC50 |
0.16 μM
Compound: 13, LLL12
|
Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23651330] |
| MDA-MB-468 | IC50 |
0.73 μM
Compound: LLL12
|
Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 33689932] |
| PANC-1 | IC50 |
0.16 μM
Compound: 13, LLL12
|
Cytotoxicity against human PANC1 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23651330] |
| SJRH30 | IC50 |
0.47 μM
Compound: 13, LLL12
|
Cytotoxicity against human Rh30 cells assessed as cell viability by MTT assay
Cytotoxicity against human Rh30 cells assessed as cell viability by MTT assay
|
[PMID: 23651330] |
| SK-BR-3 | IC50 |
0.16 μM
Compound: 13, LLL12
|
Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human SKBR3 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23651330] |
| U2OS | IC50 |
1 μM
Compound: 13, LLL12
|
Cytotoxicity against human U2OS cells assessed as cell viability by MTT assay
Cytotoxicity against human U2OS cells assessed as cell viability by MTT assay
|
[PMID: 23651330] |
| U-373MG ATCC | IC50 |
0.16 μM
Compound: 13, LLL12
|
Cytotoxicity against human U373 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human U373 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23651330] |
| U-373MG ATCC | IC50 |
0.86 μM
Compound: 90
|
Antiproliferative activity against human U373 cells
Antiproliferative activity against human U373 cells
|
[PMID: 30583248] |
| U-87MG ATCC | IC50 |
0.16 μM
Compound: 13, LLL12
|
Cytotoxicity against human U87 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human U87 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23651330] |
| U-87MG ATCC | IC50 |
0.21 μM
Compound: 90
|
Antiproliferative activity against human U87 cells
Antiproliferative activity against human U87 cells
|
[PMID: 30583248] |
LLL12 (0.01-1 μM; 72 h) inhibits cell viability of ovarian cancer cell lines with or without Cisplatin (0.5 μM, 2.5 μM) and Paclitaxel (0.25 μM, 0.5 μM).[1].
LLL12 (0.25-1.0 μM; 72 h) inhibit STAT3 phosphorylation (Tyr705) in ovarian cancer cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A2780, SKOV3, CAOV-3 and OVCAR5 ovarian cancer cell lines
-
Concentration:0.25, 0.5, and 1 μM for A2780 and OVCAR5; 1, 2.5, and 5 μM for SKOV3 and CAOV-3
-
Incubation Time:72 hours
-
Result:Inhibited STAT3 phosphorylation at Tyr705.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse xenografts with SJSA or OS-33 osteosarcoma cells[2]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection; once daily for 13 days
-
Result:Resulted in a significant reduction in tumor volume and tumor mass in the OS-33 and SJSA xenografted mice.
Chemical Information
-
CAS No. 1260247-42-4
-
Appearance Solid
-
Molecular Weight 303.29
-
Formula C14H9NO5S
-
Color Light yellow to yellow
-
SMILES
O=S(C(C=CC=C1C(C2=C3C=CC=C2O)=O)=C1C3=O)(N)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Puerarin mitigates cognitive decline and white matter injury via CD36-Mediated microglial phagocytosis in chronic cerebral hypoperfusion. [Abstract]2025 Jan 16:138:156396. PMID: 39827816
Solvent & Solubility
DMSO : 100 mg/mL (329.72 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhang R, et al. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells. Oncol Rep. 2020 Sep;44(3):1224-1232. [Content Brief]
[2]. Onimoe GI, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012 Jun;30(3):916-26. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2972 mL | 16.4859 mL | 32.9717 mL | 82.4294 mL |
| 5 mM | 0.6594 mL | 3.2972 mL | 6.5943 mL | 16.4859 mL | |
| 10 mM | 0.3297 mL | 1.6486 mL | 3.2972 mL | 8.2429 mL | |
| 15 mM | 0.2198 mL | 1.0991 mL | 2.1981 mL | 5.4953 mL | |
| 20 mM | 0.1649 mL | 0.8243 mL | 1.6486 mL | 4.1215 mL | |
| 25 mM | 0.1319 mL | 0.6594 mL | 1.3189 mL | 3.2972 mL | |
| 30 mM | 0.1099 mL | 0.5495 mL | 1.0991 mL | 2.7476 mL | |
| 40 mM | 0.0824 mL | 0.4121 mL | 0.8243 mL | 2.0607 mL | |
| 50 mM | 0.0659 mL | 0.3297 mL | 0.6594 mL | 1.6486 mL | |
| 60 mM | 0.0550 mL | 0.2748 mL | 0.5495 mL | 1.3738 mL | |
| 80 mM | 0.0412 mL | 0.2061 mL | 0.4121 mL | 1.0304 mL | |
| 100 mM | 0.0330 mL | 0.1649 mL | 0.3297 mL | 0.8243 mL |
Powered by Bioz